---
schema_version: "secwatch.filing_event.v1"
accession: "0001339970-26-000051"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2026-08-07T20:04:16+00:00"
generated_at: "2026-08-07T20:05:21.556078+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma restructures: 60% workforce cut, CFO change, $58.9M cash, Phase 3 protocol pending FDA

## Summary
- Workforce reduction of ~60% and annualized opex savings of ~$13M starting Q4 2026.
- CFO Jill Broadfoot steps down Sept 30, 2026; Brandon Yaras becomes CFO Oct 1, 2026.
- Q2 2026 cash $58.9M; runway into late 2028; R&D $6.7M, G&A $4.1M.
- Phase 3 protocol for efzofitimod in pulmonary sarcoidosis submitted to FDA June 2026; feedback expected by end of August 2026.
- Phase 2 EFZO-CONNECT in SSc-ILD enrollment completed; topline results expected Q1 2027.

## SEC filing metadata
- accession: 0001339970-26-000051
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2026-08-07T20:04:16+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/0001339970-26-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-20260807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001339970-26-000051
- JSON: https://secwatch.observer/filing/0001339970-26-000051.json
- Plain text: https://secwatch.observer/filing/0001339970-26-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.